PD-L1 Expression as a Predictor of Response to Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer. Journal of Evidence-Based Medical Research, [S. l.], v. 2, n. 03, p. 58–69, 2026. DOI: 10.66687/jebmr.2.03.2026.43. Disponível em: https://jebmr.com/index.php/home/article/view/43. Acesso em: 4 oct. 2026.